A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients with Solid Tumors and in Combination with Temozolomide in Patients with Advanced and/or Metastatic Melanoma
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2015
At a glance
- Drugs Lenvatinib (Primary) ; Temozolomide
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Jan 2015 Planned primary completion date changed from 1 Nov 2011 to 1 Sep 2011, as reported by ClinicalTrials.gov.
- 27 Jan 2015 Status changed from completed to active, no longer recruiting, as reported by ClinicalTrials.gov.